-
Russian barrage on Ukraine kills 15, wounds dozens more
-
Trump warns Iran to open Hormuz or get 'hit very hard'
-
South Korea police raid Starbucks HQ over 'Tank Day' fiasco
-
Factories shed workers in Bangladesh garment sector
-
Tech back in fashion as Asian markets extend rebound
-
North Korea warns of 'military options' over Japan rearmament
-
Total eclipse gives scientists chance to probe Sun's mysteries
-
Tiny light, big dream: Harvesting power from soil in Japan
-
What to know about the total solar eclipse on August 12
-
Trump admin to review 'closed' AI models before release: reports
-
'Like the end of the world': the eclipse chasers flocking to Spain
-
De Minaur fights past Duckworth in all-Aussie Montreal battle
-
Taiwan begins military drills as China pressure grows
-
High bills, cheap panels drive a Philippine solar surge
-
UK mansion where 'listeners' spied on Nazi generals becomes museum
-
Russian barrage on Ukraine kills 2, wounds dozens more
-
Sabalenka tops Uchijima in WTA Toronto opener
-
Alcaraz withdraws from Cincinnati Masters with wrist injury
-
Kgatlana strikes as South Africa reach WAFCON quarter-finals
-
SpaceX revenue jumps 92% in first earnings report, but shares slide
-
Pakistan close on series-levelling win against West Indies
-
US eyes Hormuz deal 'today or tomorrow' as ship sinks in Red Sea
-
Paramount CEO says politics fueling Warner Bros. merger battle
-
SpaceX revenue jumps 92% in first earnings report
-
Trump's sale of access to Truth Social raises eyebrows
-
New commissioner Berg wants to take MLS to 'next level'
-
SpaceX rocket stage expected to slam into Moon
-
Colombian ex-guerrillas fear for future under hardline president
-
US hopeful Hormuz strait deal will be done 'today or tomorrow'
-
Tsitsipas comeback continues with Montreal first-round win
-
Michigan primary puts Democratic divide on the ballot
-
Swiatek fends off Bejlek to reach Toronto third round
-
South Africa captain Kolisi to make Test return in Argentina
-
Reusser romps to overall lead at Tour de France Femmes
-
Cuba's famed resilience comes at a growing mental cost
-
McDonald's reports slower US sales in 2nd quarter
-
Swiss Reusser wins Tour de France Femmes time-trial
-
Arsenal step up bid to sign Newcastle's Guimaraes: reports
-
Hundreds flee homes after Guatemala's Fuego volcano erupts
-
Gazans hold mass funeral for those killed during war
-
Thousands pay tribute to Italian football legend Baresi
-
WHO pleads for more support to tackle Ebola outbreak
-
Oil drops, stocks hit records on hopes of Hormuz opening
-
Oil drops, stocks gain on hopes of Hormuz opening
-
Renard returns as Ivory Coast coach
-
Infantino faces nervy times to see if challenger emerges
-
Italian garbagemen help recover lost 1 mln euro lottery ticket
-
Greece gains ground against blaze near Athens
-
EU nations patch things up after Ceuta migration discord
-
Oil turns lower, stocks gain on hopes of Hormuz opening
US Justice Dept taking abortion pill fight to Supreme Court
The US Justice Department said Thursday that it will go to the Supreme Court to appeal restrictions imposed on a widely-used abortion pill in the latest round of an intensifying battle over reproductive rights.
The decision by President Joe Biden's administration came just hours after an appeals court rejected moves to ban mifepristone outright, but imposed a series of measures restricting access to the pill.
Mifepristone, which was approved by the Food and Drug Administration (FDA) in 2000 and accounts for more than half the abortions in the United States, has become the centerpiece of the country's latest clash over women's reproductive freedom.
Attorney General Merrick Garland said the Justice Department will be "seeking emergency relief from the Supreme Court to defend the FDA's scientific judgment and protect Americans' access to safe and effective reproductive care."
Speaking to reporters during Biden's visit to Dublin, Ireland, White House Press Secretary Karine Jean-Pierre said "we believe that the law is on our side, and we will prevail."
Late Wednesday, the US Fifth Circuit Court of Appeals said mifepristone, also known as RU 486, should remain available pending a full hearing of the case, but limited access to the first seven weeks of pregnancy, down from 10.
The appeals court also said in-person visits would be necessary to obtain the pill -- a requirement lifted in recent years -- and blocked the medication from being sent by mail.
The 2-1 ruling by the conservative-majority appeals court in New Orleans, Louisiana, came after a US District Court judge in Texas overturned the FDA's two-decades old approval of the drug last Friday.
- 'Furious' -
The appeals court said anti-abortion opponents had waited too long to challenge the drug's approval by the FDA but the judges' decision to impose restrictions on its use was denounced by groups seeking to maintain access to abortion.
"We are furious that yet another court would choose to jeopardize the health and futures of the millions of people who rely on mifepristone for abortion care," said Planned Parenthood president Alexis McGill Johnson.
Jennifer Dalven, director of the ACLU Reproductive Freedom Project, said "unless the Supreme Court steps in, this decision will prevent many people from getting abortion care and force them to remain pregnant against their will."
The anti-abortion group Susan B. Anthony described the appeals court ruling by two judges appointed by former Republican president Donald Trump as a "win."
"The court recognized that the abortion pill is dangerous and rolled back Biden's reckless mail-order abortion scheme," said Susan B. Anthony state policy director Katie Daniel. "We look forward to the Supreme Court hearing this case."
The latest standoff over abortion rights comes nearly a year after the Supreme Court, where conservatives wield a 6-3 majority, overturned the landmark Roe v. Wade ruling that had enshrined the constitutional right to abortion for half a century.
Mifepristone is one component of a two-drug regimen that can be used in the United States through the first 10 weeks of pregnancy.
It has a long safety record, and the FDA estimates 5.6 million Americans have used it to terminate pregnancies since it was approved.
- 'Unborn human' -
Last week's ruling by Judge Matthew Kacsmaryk, also a Trump appointee, seeking to impose a nationwide ban on mifepristone came in response to a suit by a coalition of anti-abortion groups.
The judge, in his decision, adopted language used by abortion opponents, saying the drug was used to "kill the unborn human."
Kacsmaryk said the two-drug regimen that includes mifepristone had resulted in "thousands of adverse events suffered by women and girls," including intense bleeding and psychological trauma.
But the FDA, researchers and the drugmaker say decades of experience have proven the medication to be safe and effective when used as indicated.
The Biden administration and leading pharmaceutical and biotech companies also argued that Kacsmaryk's ruling risked undermining the entire drug approval authority of the FDA.
"If this decision stands, no medication -- from chemotherapy drugs, to asthma medicine, to blood pressure pills, to insulin -- would be safe from attacks," said Vice President Kamala Harris.
Polls repeatedly show a clear majority of Americans support continued access to safe abortion, even as conservative groups push to limit access to the procedure -- or ban it outright.
A.Gasser--BTB